85% better digestion
Eli Lilly's May 21, 2026 announcement reported mean body-weight reduction of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg, compared with 2.2% on placebo [1][2]
Trials with older GLP-1 drugs (liraglutide, exenatide) including the large ADJUNCT ONE and ADJUNCT TWO studies showed modest HbA1c improvements of 0.10.7%, meaningful weight loss, and lower insulin requirements, but also raised early concerns about hypoglycemia and ketosis that kept enthusiasm in check for years
It is designed for people who are getting on well with the standard 2.4mg injection, but have found their weight loss has stopped
A study extension also found that people with a starting BMI of 35 or above who continued treatment to 104 weeks lost up to an average of 30.3% of their body weight
Semaglutide binds to albumin (a protein in the blood), which protects it from rapid degradation and extends its presence in the circulation